Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 8-9, 2009, Pages 1731-1738

  Xue, Aiqun ^a   Xue, Meilang ^b   Jackson, Christopher ^b   Smith, Ross C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Pancreatic neoplasms; Proliferation and migration; Small interfering RNA; Urokinase plasminogen activator receptor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 2; SMALL INTERFERING RNA; UROKINASE; UROKINASE RECEPTOR;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA;

ADENOCARCINOMA; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 67349218408     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.03.004     Document Type: Article

References (41)

1. Allgayer H., and guirre-Ghiso J.A. The urokinase receptor (u-PAR)-a link between tumor cell dormancy and minimal residual disease in bone marrow?. APMIS 116 (2008) 602-614
2. Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72 (1997) 1-22
3. Bauer T.W., Liu W., Fan F., Camp E.R., Yang A., Somcio R.J., et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65 (2005) 7775-7781
4. Bessard A., Fremin C., Ezan F., Coutant A., and Baffet G. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 212 (2007) 526-536
5. 0 in primary avian fibroblasts. Curr Biol 10 (2000) 1119-1122
6. Cobb M.H. MAP kinase pathways. Prog Biophys Mol Biol 71 (1999) 479-500
7. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
8. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., et al. Plasminogen activation and cancer. Thromb Haemost 93 (2005) 676-681
9. Dong Z., Saliganan A.D., Meng H., Nabha S.M., Sabbota A.L., Sheng S., et al. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 10 (2008) 439-449
10. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10 (2004) 39-49
11. Estreicher A., Muhlhauser J., Carpentier J.L., Orci L., and Vassalli J.D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111 (1990) 783-792
12. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60 (2000) 636-643
13. Friedl P., and Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3 (2003) 362-374
14. Gao K., Dai D.L., Martinka M., and Li G. Prognostic significance of nuclear factor-kappaB p105/p50 in human melanoma and its role in cell migration. Cancer Res 66 (2006) 8382-8388
15. guirre-Ghiso J.A., Kovalski K., and Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147 (1999) 89-104
16. guirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7 (2007) 834-846
17. guirre-Ghiso J.A., Estrada Y., Liu D., and Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63 (2003) 1684-1695
18. guirre-Ghiso J.A., Liu D., Mignatti A., Kovalski K., and Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12 (2001) 863-879
19. guirre-Ghiso J.A., Ossowski L., and Rosenbaum S.K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64 (2004) 7336-7345
20. Gyetko M.R., Todd III R.F., Wilkinson C.C., and Sitrin R.G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93 (1994) 1380-1387
21. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
22. Hotz M.A., Gong J., Traganos F., and Darzynkiewicz Z. Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 15 (1994) 237-244
23. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106-130
24. Konakova M., Hucho F., and Schleuning W.D. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem 253 (1998) 421-429
25. Kotzsch M., Sieuwerts A.M., Grosser M., Meye A., Fuessel S., Meijer-van Gelder M.E., et al. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat 111 (2008) 229-240
26. Liu D., Aguirre G.J., Estrada Y., and Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 (2002) 445-457
27. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94 (2002) 116-128
28. Ma Z., Webb D.J., Jo M., and Gonias S.L. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114 (2001) 3387-3396
29. Maitra A., and Hruban R.H. Pancreatic cancer. Annu Rev Pathol 3 (2008) 157-188
30. Mazzieri R., and Blasi F. The urokinase receptor and the regulation of cell proliferation. Thromb Haemost 93 (2005) 641-646
31. Nielsen A., Scarlett C.J., Samra J.S., Gill A., Li Y., Allen B.J., et al. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 20 (2005) 256-263
32. Ossowski L., and Reich E. Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 33 (1983) 323-333
33. Qu C.F., Song E.Y., Li Y., Rizvi S.M., Raja C., Smith R., et al. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 22 (2005) 575-586
34. Ribble D., Goldstein N.B., Norris D.A., and Shellman Y.G. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 5 (2005) 12
35. Sehgal I., Foster T.P., and Francis J. Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis. Cancer Cell Int 6 (2006) 21
36. Smith R., Xue A., Gill A., Scarlett C., Saxby A., Clarkson A., et al. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 31 (2007) 493-502
37. Vial E., Sahai E., and Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4 (2003) 67-79
38. Xue A., Scarlett C.J., Jackson C.J., Allen B.J., and Smith R.C. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 36 (2008) 160-167
39. Xue M., Campbell D., and Jackson C.J. Protein C is an autocrine growth factor for human skin keratinocytes. J Biol Chem 282 (2007) 13610-13616
40. Yang L., Avila H., Wang H., Trevino J., Gallick G.E., Kitadai Y., et al. Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density-implications in tumor progression. Cancer Res 66 (2006) 7957-7967
41. Zorio E., Gilabert-Estelles J., Espana F., Ramon L.A., Cosin R., and Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 15 (2008) 923-929